[Skip to content]

Private Healthcare UK
Search our Site

This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.


Dr Timothy Perren

Dr Timothy Perren
Job title
Consultant Medical Oncologist
Primary specialtyOncology
Year qualified
Date of GMC registration (dd/mm/yyyy)
Pen Picture
Dr Perren is a consultant medical oncologist specialising in the non-surgical treatment of cancers using chemotherapy, hormonal therapy and the new molecular therapies such as Herceptin. Modern treatment for cancer requires the careful integration of diagnostic procedures, surgical treatment and medical therapies and treatment is becoming increasingly tailored to the patient and their cancer. Dr Perren is a member of the multidisciplinary teams for breast cancer and gynaecological cancers at the Leeds Teaching Hospitals NHS Trust and works with the same team of surgeons, radiologists and pathologists in the private sector as he does in the NHS. Through his NHS practice he is involved in many research trials investigating the integration of new treatments into cancer care. He is author or co-author of around 100 research papers and abstracts. Dr Perren trained in general medicine in London and in Stoke on Trent; and is a fellow of the Royal College of Physicians. His oncology training was in Birmingham and the Royal Marsden Hospital. He was appointed consultant medical oncologist at St James's Hospital in Leeds in January 1990.
Clinical interests
Dr Perren specialises in the treatment of: • breast cancer • gynaecological cancers (including ovarian cancer, cervical cancer and endometrial cancer) As a Medical Oncologist he specialises in the use of medical treatments for cancer including cytotoxic chemotherapy, hormonal therapy, and the rapidly emerging field of targeted molecular therapies such as Herceptin (trastuzumab), Avastin (bevacizumab), Tykerb (lapatinib). He provides treatment for newly diagnosed patients, as well as for those with recurrent or metastatic disease. He also has considerable experience in the treatment of the difficult constellation of symptoms that can often accompany cancer and its treatment. Modern oncology treatments require the careful integration of the results of laboratory and radiological investigations with the latest scientific knowledge about the disease and its treatment. Historically we used the same toxic treatments for all patients with a given condition; with modern diagnostics it is becoming increasingly possible to tailor treatments to the requirements of individual patients and their diseases. Cancer treatments are however complex and in deciding the best treatment for any individual there are many choices to be made. Dr Perren's philosophy of patient care puts the patient at the centre of treatment planning. He believes in discussing all options of treatment before finally coming up with a solution that is best for the individual concerned.
Research interests
Through his NHS practice Dr Perren is involved in many clinical research trials investigating the integration of new treatments into cancer care. It is of course only through research that further improvements in cancer care will be made. He is also interested in translational research which is scientific or laboratory research which is carried out on samples of tumour or blood taken from patients entered into treatment trials. Through this sort of research it will be possible to identify particular characteristics about patients or cancers which in the future might help us to better target our treatments to those patients who will truly benefit from them, whilst sparing those who will not benefit from them from the toxicities and side effects of those treatments. Dr Perren is a member of the National Cancer Research Institute Gynaecological Cancer Clinical Studies Group as well as its endometrial cancer and ovarian cancer subgroups. He is also a member of the newly formed UK Breast Cancer Intergroup. Dr Perren is author or co-author of around 100 research papers and abstracts.
Professional memberships
• American Society of Clinical Oncology
• Association of Cancer Physicians
• European Society of Medical Oncology
• British Medical Association
Outcome Data/Success Rates
This is difficult for an oncologist. Outcome can be measured in many different ways. In terms of toxic death rate this would be very low indeed. In terms of 5 or 10 year survival this would depend upon the disease and the stage of that disease at the time of treatment.
Post operative infection rates
Not relevant
NHS Hospital
Leeds Teaching Hospitals NHS Trust
Private hospital/Private clinic
Spire Leeds Hospital
Jackson Avenue
West Yorkshire
Dr Timothy Perren
Jackson Avenue Roundhay
United Kingdom
Private practice tel:
0113 218 5917
Call for appointments:
0113 218 5917
0113 218 5958
Spire Accreditation for Enhanced Listing